MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

BHVN — Biohaven Ltd.

NYSE

Biohaven Ltd.

CompareBack to Screener
$12.87
-0.27(-2.05%)
O
13.41
H
13.51
L
12.63
V
1.73M
⏱️ End-of-day dataAs of Oct 2, 2026

Chart

About BHVN

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateSep 23, 2022
Employees274
Stock ExchangeNYSE
Ticker SymbolBHVN

Key Financial Statistics

Market Cap$1.96B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$7.48 - $18.57
52-Week Avg Volume3.00M
VWAP$12.87
Transactions21,341
Total Recorded Bars1,010 days